Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes

Y Kimoto1, T Taguchi

  • 1Department of Oncologic Surgery, Osaka University, Japan.

Biken Journal
|June 1, 1987
PubMed

Lymphokine activated killer cells (LAK cells) or interleukin 2 (IL-2)-activated killer cells were induced by recombinant IL-2 (TGP-3) for clinical adoptive immunotherapy of malignant diseases. After incubation of peripheral blood lymphocytes (PBL) with IL-2 and normal human plasma for 1-2 weeks LAK cells were obtained that showed a maximum cytotoxicity against target cells, and did not need a toxic dose of IL-2 to enhance or maintain their cytotoxicity. Both autologous and allogeneic LAK cells were used in five clinical cases without any immune side effects, and were effective in three cases.

Related Concept Videos